Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
RTW Biotech delivered an impressive +15.5% Q4 return (+35.7% YTD) amid a macro biotech rebound, expanding its buybacks and securing new private-to-public arbitrage opportunities.
Full Quick Take
RTW Biotech delivered an impressive +15.5% Q4 return (+35.7% YTD) amid a macro biotech rebound, expanding its buybacks and securing new private-to-public arbitrage opportunities.
RTW Biotech generated a strong 7.8% MTD return in July 2025, buoyed by notable M&A exits and rumors, despite temporary US political and drug-pricing headwinds.
Full Quick Take
RTW Biotech generated a strong 7.8% MTD return in July 2025, buoyed by notable M&A exits and rumors, despite temporary US political and drug-pricing headwinds.
